.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

SEROQUEL XR Drug Profile

« Back to Dashboard
Seroquel Xr is a drug marketed by Astrazeneca and is included in one NDA. It is available from five suppliers. There is one patent protecting this drug and four Paragraph IV challenges.

The generic ingredient in SEROQUEL XR is quetiapine fumarate. There are fifty drug master file entries for this compound. Fifty-two suppliers are listed for this compound. There are four tentative approvals for this compound. Additional details are available on the quetiapine fumarate profile page.

Summary for Tradename: SEROQUEL XR

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list5
Drug Prices: :see details

Pharmacology for Tradename: SEROQUEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-001May 17, 2007RXNo5,948,437*PED► subscribeY► subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-003May 17, 2007RXNo5,948,437*PED► subscribeY► subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-005Aug 11, 2008RXNo5,948,437*PED► subscribeY► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SEROQUEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-001May 17, 20074,879,288*PED► subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-005Aug 11, 20084,879,288*PED► subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-004May 17, 20074,879,288*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SEROQUEL XR

Drugname Dosage Strength RLD Submissiondate
quetiapine fumarateExtended-release Tablets150 mgSeroquel XR11/17/2008
quetiapine fumarateExtended-release Tablets50 mgSeroquel XR10/17/2008
quetiapine fumarateExtended-release Tablets400 mgSeroquel XR6/18/2008
quetiapine fumarateTablets200 mg and 300 mgSeroquel XR6/12/2008
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc